About this episode
There’s a massive biotech buyout underway, with Biogen paying over $6 billion to bulk up its rare disease portfolio. We’ll explore the “arms race” brewing in big pharma.
Plus, we have more ‘power players’ joining the show. Valley Bank’s CEO gives us a read on rising rates and new bank rules, while the Union Square Hospitality Group CEO gives us insight into the consumer.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time Power Lunch publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Power Lunch
September Rate Hike Odds, Middle East Oil Disruptions, AI Researcher Resignation...
Power Lunch
Thoma Bravo Founder, Treasury Bond Auction, Terawulf Exclusive 9/10/26
Power Lunch
Apple’s Foldable iPhone, Brent Tops $100, AT&T CEO Interview 9/9/26
Power Lunch
State of the Markets, Diesel Prices at Record Highs, Regional Bank Merger 9/8/26
Power Lunch